Shine Justice Ltd Overview
Shine Justice is one of very few publicly listed law firms globally and the parent of Shine Lawyers, a 50-year-old Australian plaintiff litigation group that operates predominantly on a no-win-no-fee basis. Its economic engine is Personal Injury (86% of FY26 statutory revenue and income), where it holds an estimated 8.5% share of a fragmented A$2.0 billion market and resolves 4,000+ matters a year, securing over A$800 million in damages. The second segment, Class Actions, is a higher-variance, higher-ticket practice that has produced landmark First Nations Stolen Wages settlements and is now being internationalised through a US "hub" (Shine Lawyers US, LLC in Arizona) that sources mass torts for Australian, New Zealand and Thai "spokes". The investment case rests on converting a A$366.6 million work-in-progress (WIP) book into cash, restoring earnings quality after repeated legacy write-downs, and proving that AI-enabled workflows and international mass torts can lift returns from a low single-digit ROE base.
Company's own description (FY26 Annual Report / Presentation)
The company describes itself as an ASX-listed Australian legal group and parent of Shine Lawyers, one of the nation's largest plaintiff law firms, helping everyday people and communities access justice through a predominantly no-win-no-fee model across two operating segments — Personal Injury and Class Actions — with a growing New Zealand and international mass-torts capability (FY26 Investor Presentation, slide 3). The Directors' Report states that during FY26 the Group provided plaintiff legal services in Australia, New Zealand and Arizona, USA, across those two core segments, with no significant change in the nature of activities. Its stated purpose is to "shine a light on injustice" and its values include standing up for "the little guy".
Business model and revenue model
| Revenue type (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
| No-win-no-fee variable (PI) | 156.9 | 168.3 |
| No-win-no-fee fixed (PI) | 9.4 | 11.3 |
| Time and materials (PI) | 0.0 | 1.3 |
| No-win-no-fee variable (Class Action) | 28.6 | 20.5 |
| Time and materials (Class Action) | 5.5 | 3.3 |
| Insurance (Class Action segment) | 4.0 | 4.3 |
| Interest and other income (Corporate) | 1.5 | 0.2 |
| Total revenue and other income | 205.9 | 209.4 |
Shine is a contingent-fee professional services business. It funds legal work and client disbursements (medical reports, expert witnesses, court fees) on balance sheet until a matter resolves, then bills fees from settlement or judgment proceeds. Accounting under AASB 15 recognises revenue over time as work is performed, net of a "constraint" for variable consideration; unbilled work sits on balance sheet as contract assets — work in progress (A$366.6m at 30 Jun 2026, net of a A$129.5m constraint, up from A$105.1m), and recoverable disbursements are carried as a separate fair-valued financial asset (A$102.6m).
FY26 revenue and income mix by contract type (A$m, FY26 AR Note 1A):
On this basis roughly 96% of FY26 revenue is contingent ("service" revenue with success-based pricing); time-and-materials work is ~2% and an insurance-services line ~2%. There is no product, subscription or licensing revenue. No single customer exceeds 10% of revenue (FY26 AR).
Value chain position
Shine sits at the client-acquisition and litigation-execution end of the plaintiff legal value chain: it markets directly to consumers (media agency of record dentsu Queensland appointed September 2025; CMO Shannan Madden), operates an intake/CRM platform built on Salesforce, runs matters through to settlement, and administers settlement distributions in some class actions. Upstream it relies on litigation funders (third-party funding for larger class actions; a new international facility of up to A$40m secured in FY26) and disbursement suppliers. Counterparties are compulsory third-party (CTP) motor insurers, workers' compensation schemes, public liability insurers, institutions (abuse claims), corporates, superannuation trustees and governments.
Customer types and end-markets
Individuals: injured in motor accidents, workplaces, public places, medical settings; survivors of institutional abuse; sufferers of dust diseases; superannuation/total-and-permanent-disability (TPD) insurance claimants.
Groups: in class actions across seven sectors identified in the FY26 portfolio: financial services, First Nations/social justice, shareholder, consumer, employment, medical and environmental.
International mass-tort claimants: in Australia, New Zealand and Asia (Thailand), sourced via the US hub.
Independent characterisation
Economically, Shine resembles a specialty finance business wearing a law-firm wrapper: it deploys working capital into a portfolio of litigation "options" whose payoff timing is controlled by courts, insurers and defendants. Personal Injury behaves like a granular, high-volume, statistically predictable book (5,900 new files, 4,000+ resolutions a year), which supports steady EBITDA of A$30–37m. Class Actions are lumpy, concentrated and binary: single-matter write-downs (A$32.4m Ethicon interest judgment in FY23; A$7.3m mesh revenue reversal in H1 FY24; A$13.0m legacy matter in FY26) have repeatedly overwhelmed segment profits. The key analytical variables are therefore WIP recoverability, constraint levels, cash conversion and funding terms — not revenue growth alone.
Strategy
Stated strategy (2026 AR, Operating and Financial Review)
Shine's strategy rests on six pillars: prioritise our client; engage our people; grow Shine; strengthen Shine; innovate Shine; and — added by the Board in FY26 — internationalise Shine, recognising the US presence as central to the Group's future. The FY26 Presentation organises the agenda into three workstreams:
Scale Personal Injury: maintain productivity and recoverability momentum; grow suitable file volumes; pursue disciplined acquisitions; improve conversion and branch performance.
Build the Class Action Engine: raise investigation-to-filing velocity; improve matter selection and governance; advance external funding; progress Australian, NZ, Thai and other international opportunities.
Improve Cash and Efficiency: convert WIP into billed fees and cash; scale technology-supported workflows; maintain cost and capital discipline; preserve facility and covenant headroom.
Initiatives announced in the last 24 months
| Initiative | Timing | Detail / target | Source |
|---|---|---|---|
| Shine Lawyers US, LLC (Arizona) | FY25 | ABS-licensed entity allowing non-lawyer ownership; IMT hub | FY25 Results; 2026 AR |
| International mass torts hub-and-spoke model | FY25–FY26 | Source large US mass torts, export to AU/NZ/Asia spokes, secure funding, litigate | FY26 Presentation |
| A$40m international funding facility | FY26 | Funds a large-scale mass tort class action in Australia | 2026 AR |
| Shine Lawyers (Thailand) Co. Ltd | FY26 | Asia spoke; Morrison-affiliated, loan-funded | 2026 AR |
| Emerging Technology Centre and AI roadmap | FY25–FY28 | Foundation (FY25), proof of concept (FY26), acceleration (FY27), maturity with agentic workflows (FY28) | FY26 Presentation |
| Class action portfolio funding | FY26–FY27 | "Well progressed" discussions to fund a portfolio of matters, reducing timing risk | FY26 Presentation |
| PI file acquisitions | FY26 | 180 files acquired, "opportunity for more" | FY26 Presentation |
| Disbursement refinancing | FY25–FY26 | Final externally funded disbursements moved to bank facility for interest savings | 2026 AR |
| Bank facilities renewed and extended | FY25 | A$119.7m facilities to March 2028 | FY25 Results; FY26 Presentation |
| Capital management | Sep 2024 – Oct 2026 | Buy-backs; fully franked dividends with 30–50% NPAT payout policy | 2026 AR |
| Marketing re-platform | Sep 2025 | dentsu Queensland media agency of record | dentsu release |
| Regional outreach program | 2,026 | Tours to regional, rural, remote communities | 2026 AR |
| Third Reconciliation Action Plan | FY26 | Second "Innovate" RAP being finalised | 2026 AR |
Guidance and medium-term targets
No quantified medium-term targets are published. FY27 guidance is qualitative: the Board "expects to deliver improved EBITDA and operating cash flow in FY27 across our personal injury, class action and emerging international mass tort practice" (Chairman's Letter), with growth in profitability in both segments alongside higher group cash flow (FY26 Presentation). Implicit LTI targets — 8–10% p.a. EPS growth from a 12c base and 15–17% p.a. TSR through FY28 — indicate management's aspirational trajectory.
Products & Services
Pricing across PI is predominantly no-win-no-fee (fees regulated in several states); class actions use contingency structures, funder commissions, Federal Court/Victorian group costs orders (GCOs) and uplift fees. Launch years are generally not disclosed for practice areas.
Personal Injury segment (FY26 revenue and income A$180.9m)
| Service line | Description and capabilities | Target client | Pricing model |
|---|---|---|---|
| Motor vehicle accident / CTP claims | Statutory and common law claims under state CTP schemes | Injured drivers, passengers, pedestrians, cyclists | No-win-no-fee; regulated in some states |
| Workers' compensation | Statutory benefits and common law damages; Morrison is a QLS Accredited Specialist in PI | Injured workers | No-win-no-fee |
| Public liability | Slip-and-fall, occupiers' liability, product injury | General public | No-win-no-fee |
| Medical law (medical negligence) | Clinical negligence claims; cited as a FY23 growth driver | Patients and families | No-win-no-fee |
| Abuse law | Institutional child sexual abuse claims; CLO Lisa Flynn provided evidence to Royal Commissions | Survivors | No-win-no-fee |
| Dust diseases | Asbestos, silica claims; record A$3.2m judgment in NSW Dust Diseases Tribunal (FY25) | Mesothelioma/silicosis sufferers | No-win-no-fee |
| Superannuation and disability insurance | TPD, income protection, life insurance claims | Super fund members | No-win-no-fee; fixed-fee (A$11.3m FY26) |
| Stephen Browne Lawyers (WA brand) | Western Australian PI subsidiary brand | WA claimants | No-win-no-fee |
| Shine Lawyers NZ | Accident and insurance recovery work in NZ (affiliate consolidated from 7 Nov 2024) | NZ claimants | Mixed |
FY26 PI KPIs: 5,900+ new files; 4,000+ clients compensated; A$800m+ damages; 180 files acquired; new file fees +9%; 47 PI offices; 540+ PI staff (FY26 Presentation; 2026 AR).
Class Action segment (FY26 adjusted revenue A$39.4m)
| Service line / flagship matter | Description | Status (latest disclosed) |
|---|---|---|
| Domestic class actions — financial services | Super insurance overcharging (Colonial First State/CMLA/AIA, A$140m; QSuper A$67m; CommInsure two settlements; AMP) | CFS settlement hearing scheduled 25 Mar 2026 (Federal Court notice); AMP Super proceedings filed |
| Shareholder class actions | EML Payments (A$37.2–37.3m settlement; 24.5% GCO) | Settled; fee variation bid withdrawn (Lawyerly) |
| First Nations / social justice | NT Stolen Wages (up to A$202m), WA Stolen Wages (up to A$180.4m); WA and NSW child-removal discrimination actions | Stolen Wages paid to majority of members; discrimination actions ongoing |
| Employment | KFC rest breaks (A$28.8m, with Gordon Legal, RAFFWU/SDA); SA Sunday penalty rates; other retail rest-break actions (Coles, Woolworths, McDonald's, Big W, Hungry Jack's alleged) | KFC final approval hearing scheduled Sep 2026 |
| Consumer, medical, environmental | Pipeline incl. pharmaceuticals, product liability; historical mesh, contamination (Wreck Bay, multi-site PFAS) matters | 6 consumer and 6 medical matters under investigation |
| International mass torts (IMT) | US hub (Shine Lawyers US, LLC, Arizona) sources mass torts for AU/NZ/Thailand spokes; A$40m funding facility | Several investigations "well progressed" |
| New Zealand class actions | Hino Motors (first NZ class action win/settlement) | Resolved FY26 |
| Commercial disputes | Legacy practice | In wind-down |
| Family law | Small T&M practice within CA segment | Ongoing |
| Insurance services | A$4.3m FY26 revenue under AASB 17 (Note 9) | Ongoing |
Portfolio at FY26: ~48 open matters — 26 active, 22 investigations; filed actions led by financial services (7) (FY26 Presentation). Six in-principle settlements in FY26 totalling >A$290m.
Technology platforms (internal, not sold)
| Platform | Capability | Year |
|---|---|---|
| Emerging Technology Centre | Cluster of data scientists and IT staff governed by steering committee | Established FY25; scaled FY26 |
| AI governance framework | Enterprise policy for procurement, development, deployment of AI | Implemented FY26 |
| Agentic and automation platform | Foundation for workflow automation and AI agents | Established FY26 |
| Salesforce client intake | CRM for enquiry management, now AI-enhanced | Deployed FY25 |
| Data platform | Reporting, analytics, future AI | Established FY26 |
| People and payroll platform | Unified HR/payroll | Implementation commenced FY26 |
Financial Narrative
Margins and growth
Adjusted margins for FY26 use adjusted revenue of A$220.4m. Revenue CAGR FY22–FY26: –0.7% p.a. (statutory, restated basis). On an adjusted basis FY26 revenue of A$220.4m implies a +0.6% CAGR from FY22.
Commentary. The five-year arc is a sharp de-rating of earnings quality. FY22 was the high-water mark (29.5% statutory EBITDA margin), inflated by class action fee recognition. FY23 was hit by the A$32.4m Ethicon interest judgment; FY24 by A$7.3m of mesh revenue reversals and restructuring costs; FY25 by a A$9.6m deferred consideration write-down; FY26 by the A$13.0m legacy class action charge. The recurring nature of "one-off" items is itself the most important analytical finding: adjusted EBITDA has averaged A$50.7m over five years while statutory EBITDA averaged A$37.8m. The constructive inflection in FY26 is in Personal Injury, where EBITDA grew 18.4% and margins expanded, and in cost control (employee costs +3.8% vs adjusted revenue +7.8%).
Balance sheet (30 June)
Sources: 2026 AR balance sheet; FY24 cash from 2026 AR cash flow opening balance; FY24 WIP from FY25 results; FY24 equity from 2026 AR statement of changes in equity; NTA per Appendix 4E/InvestSMART. The large deferred tax liability reflects tax being payable only when WIP is billed.
Cash flow
Commentary. Operating cash flow has been stable at ~A$19m but is not covering dividends plus lease payments plus capex: FY26 post-lease FCF of A$7.0m funded less than the A$8.5m dividend, with the shortfall drawn from cash. The FY25 refinancing of disbursement funding into bank debt lowered the P&L finance cost (–14%) but raised cash interest paid (A$10.6m vs A$8.0m). Management guides to higher operating cash flow in FY27 as WIP converts.
Ratios
All ratios are analyst calculations from 2026 AR figures except payout (2026 AR). A conventional cash conversion cycle is not meaningful; WIP days of ~640 (i.e., roughly 21 months of revenue tied up in unbilled work) is the relevant working-capital metric. Facility headroom was A$41.4m on A$119.7m of facilities maturing March 2028; all covenants met (FY26 Presentation).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key services |
|---|---|---|
Personal Injury | Core damages-based plaintiff practice | Motor accidents (CTP), workers' compensation, public liability, medical law, abuse law, dust diseases; superannuation and disability insurance claims |
Class Action | Growth practice | Domestic class actions, international mass torts (IMT), commercial disputes (in wind-down), family law, insurance services line |
Other | Corporate | Head office, group services, interest income |
Revenue by Segment
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Personal Injury revenue and income (AUD Mn) | — | 166.3 | 180.9 |
Class Action revenue and income — statutory (AUD Mn) | — | 38.1 | 28.2 |
Class Action revenue — adjusted (AUD Mn) | 35.0 | 38.1 | 39.4 |
Other / corporate income (AUD Mn) | — | 1.5 | 0.3 |
Group revenue and income (AUD Mn) | — | 205.9 | 209.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Personal Injury EBITDA (AUD Mn) | — | 30.9 | 36.6 |
Personal Injury EBITDA margin (%) | — | 18.6 | 20.2 |
Class Action EBITDA — statutory (AUD Mn) | — | 7.7 | -4.8 |
Class Action EBITDA — adjusted (AUD Mn) | 8.3 | 7.7 | 8.2 |
Class Action adjusted EBITDA margin (%) | 23.7 | 20.2 | 20.8 |
Other / corporate EBITDA (AUD Mn) | — | -9.0 | -0.1 |
Group statutory EBITDA (AUD Mn) | 34.7 | 29.7 | 31.7 |
Segment growth and mix (%)
| Segment growth and mix (%) | FY2025 | FY2026 |
|---|---|---|
Personal Injury revenue YoY growth (%) | — | 8.8 |
Personal Injury EBITDA YoY growth (%) | — | 18.4 |
Class Action adjusted revenue YoY growth (%) | 8.9 | 3.4 |
Class Action adjusted EBITDA YoY growth (%) | -7.2 | 6.5 |
Personal Injury share of group revenue and income (%) | 80.8 | 86.4 |
Class Action share of group revenue and income (%) | 18.5 | 13.5 |
Segment cost and capital (AUD Mn)
| Segment cost and capital (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
PI employee benefits | 69.1 | 71.4 |
PI other expenses | 18.2 | 19.6 |
PI inter-segment recharges | 48.1 | 53.3 |
CA employee benefits | 19.1 | 18.3 |
CA other expenses | 4.0 | 7.1 |
CA inter-segment recharges | 7.3 | 7.5 |
PI segment assets | 463.4 | 483.2 |
CA segment assets | 109.8 | 90.1 |
PI segment liabilities | 99.8 | 99.1 |
CA segment liabilities | 44.9 | 44.3 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 215.1 | 226.2 | 195.7 | 204.4 | 209.2 |
EBITDA — statutory (AUD Mn) | 63.4 | 29.6 | 34.7 | 29.7 | 31.7 |
EBITDA — adjusted (AUD Mn) | 63.1 | 61.6 | 45.0 | 39.3 | 44.7 |
Depreciation and amortisation (AUD Mn) | — | — | 15.4 | 16.0 | 13.6 |
EBIT / operating income (AUD Mn) | — | — | 19.3 | 13.7 | 18.1 |
Finance costs (AUD Mn) | — | — | — | 9.2 | 7.9 |
Profit before tax (AUD Mn) | — | — | — | 4.5 | 10.2 |
NPAT — total incl. NCI (AUD Mn) | 31.2 | 3.3 | 6.0 | 0.1 | 6.7 |
NPAT attributable to owners (AUD Mn) | 31.1 | 3.3 | 6.0 | 0.6 | 9.6 |
NPAT — adjusted (AUD Mn) | — | — | — | 9.7 | 15.8 |
Basic EPS (A$ cents) | 18.0 | 1.92 | 3.51 | 0.33 | 5.74 |
Diluted EPS (A$ cents) | — | — | — | 0.33 | 5.66 |
Adjusted basic EPS (A$ cents) | — | — | — | 5.96 | 11.19 |
Dividends per share (A$ cents) | 6.0 | 1.5 | 5.5 | 5.0 | 4.0 |
Cash Contribution / GOCF (AUD Mn) | 30.7 | -3.9 | 51.8 | 30.6 | 29.4 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Statutory EBITDA margin (%) | 29.5 | 13.1 | 17.7 | 14.5 | 15.2 |
Adjusted EBITDA margin (%) | 29.3 | 27.2 | 23.0 | 19.2 | 20.3 |
EBIT margin (%) | — | — | 9.9 | 6.7 | 8.7 |
Net margin — attributable (%) | 14.5 | 1.5 | 3.1 | 0.3 | 4.6 |
Revenue growth YoY (%) | — | 5.2 | -13.5 | 4.4 | 2.3 |
Balance Sheet and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total assets (AUD Mn) | — | 575.5 | 575.1 |
Cash and equivalents (AUD Mn) | 29.4 | 18.1 | 12.5 |
Contract assets — WIP (AUD Mn) | 356.4 | 363.5 | 366.6 |
Unbilled disbursements (AUD Mn) | — | 100.8 | 102.6 |
Intangibles incl. goodwill (AUD Mn) | — | 46.4 | 43.7 |
Borrowings — current (AUD Mn) | — | 26.6 | 28.7 |
Borrowings — non-current (AUD Mn) | — | 45.0 | 45.0 |
Lease liabilities (AUD Mn) | — | 27.4 | 25.1 |
Disbursement creditors (AUD Mn) | — | 71.4 | 70.5 |
Net debt incl. leases (AUD Mn) | — | 81.0 | 86.3 |
Deferred tax liability (AUD Mn) | — | 115.2 | 112.9 |
Total equity (AUD Mn) | 272.6 | 261.3 | 259.7 |
Equity attributable to owners (AUD Mn) | — | 261.6 | 262.9 |
Current assets (AUD Mn) | — | 248.4 | 273.1 |
Current liabilities (AUD Mn) | — | 130.5 | 137.3 |
Working capital (AUD Mn) | — | 117.9 | 135.8 |
WIP revenue constraint (AUD Mn) | — | 105.1 | 129.5 |
NTA per share (AUD) | 1.32 | 1.29 | 1.30 |
Cash Flow
| Metric | FY2025 | FY2026 |
|---|---|---|
Receipts from customers (AUD Mn) | 217.5 | 220.7 |
Net disbursements paid (AUD Mn) | -10.2 | -6.3 |
Interest paid net (AUD Mn) | -7.2 | -10.5 |
Income taxes paid (AUD Mn) | -6.2 | -3.4 |
Operating cash flow (AUD Mn) | 19.5 | 19.0 |
Capex — plant and equipment (AUD Mn) | 1.6 | 2.7 |
Capex — intangibles (AUD Mn) | 0.8 | 0.7 |
Free cash flow pre-leases (AUD Mn) | 17.2 | 15.6 |
Lease principal payments (AUD Mn) | 9.2 | 8.6 |
Free cash flow post-leases (AUD Mn) | 7.9 | 7.0 |
Dividends paid to shareholders (AUD Mn) | 9.5 | 8.5 |
Share buy-backs (AUD Mn) | 2.5 | 0.3 |
Net change in cash (AUD Mn) | -11.4 | -5.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE — attributable NPAT / avg owners' equity (%) | 0.2 | 3.7 |
ROE — adjusted NPAT basis (%) | 3.6 | 6.0 |
ROA — total NPAT / avg assets (%) | 0.0 | 1.2 |
ROIC — EBIT x (1-30%) / (equity + net debt) (%) | 2.8 | 3.7 |
Current ratio (x) | 1.90 | 1.99 |
Debt to equity — borrowings plus leases (x) | 0.38 | 0.38 |
Net debt to statutory EBITDA (x) | 2.73 | 2.72 |
Net debt to adjusted EBITDA (x) | 2.06 | 1.93 |
Interest coverage — EBIT / finance costs (x) | 1.5 | 2.3 |
Asset turnover (x) | 0.35 | 0.36 |
WIP days — WIP / revenue x 365 (days) | 649 | 640 |
Dividend payout — of attributable NPAT (%) | 1,490 | 71 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2025 | FY2026 |
|---|---|---|
Australia revenue (AUD Mn) | 203.0 | 207.2 |
New Zealand revenue (AUD Mn) | 1.5 | 2.0 |
Total revenue (AUD Mn) | 204.4 | 209.2 |
Region growth and mix | FY2026 | — |
Australia revenue growth YoY (%) | 2.1 | — |
New Zealand revenue growth YoY (%) | 33.7 | — |
Australia share of revenue (%) | 99.1 | — |
New Zealand share of revenue (%) | 0.9 | — |
Region Assets & Liabilities
| Region | FY2025 | FY2026 |
|---|---|---|
Australia non-current assets (AUD Mn) | 270.3 | 249.6 |
New Zealand non-current assets (AUD Mn) | 7.7 | 7.4 |
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 1.08 | 0.69 | 0.71 | 0.70 | 0.60 |
Total shareholder return (%) | 7.7 | -32.9 | 4.8 | 6.5 | -8.8 |
Dividends declared (AUD Mn) | 10.4 | 2.6 | 9.5 | 8.5 | 6.8 |
Market capitalisation (AUD Mn) | — | — | 122 | 119 | 101 |
Performance Window Details
| Performance window | Price change (%) | Notes |
|---|---|---|
1-year (Jun 2025 → Jun 2026) | -14.3 | TSR –8.8% incl. dividends |
3-year (Jun 2023 → Jun 2026) | -13.0 | — |
4-year (Jun 2022 → Jun 2026) | -44.4 | — |
Since IPO (A$1.00, May 2013) | -35.5 | All-time high A$3.45 (Halo Technologies) |
Latest observed | A$0.645 (29 Sep 2026) | 2026 range A$0.565–0.77 |
Valuation Multiples
| Multiple | Shine (statutory) | Shine (adjusted) | Peers |
|---|---|---|---|
P/E (x) | 11.2 | 5.8 | No listed pure-play peer |
EV/EBITDA (x) | 6.2 | 4.4 | — |
EV/Sales (x) | 0.93 | 0.89 | — |
P/B (x) | 0.41 | 0.41 | — |
P/NTA (x) | 0.50 | 0.50 | — |
Dividend yield, fully franked (%) | 6.2 | 6.2 | — |
“—” = not publicly disclosed.
Per-Share Data and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (A$ cents) | — | 1.5 | 1.5 | 1.5 | 1.5 |
Final DPS (A$ cents) | — | 0.0 | 4.0 | 3.5 | 2.5 |
Total DPS (A$ cents) | 6.0 | 1.5 | 5.5 | 5.0 | 4.0 |
Franking (%) | — | — | 0 | 100 | 100 |
Payout ratio of attributable NPAT (%) | 33 | 78 | 158 | 1,490 | 71 |
Capital Programmes
| Program | Period | Shares cancelled | Cost |
|---|---|---|---|
Initial on-market buy-back | Sep 2024 – Sep 2025 | 3,871,416 | A$2,759,775 |
Renewed 10% buy-back (max 16,939,039) | 3 Oct 2025 – 2 Oct 2026 | 0 per 2026 AR | Nil |
Capital Markets
| Item | Detail |
|---|---|
Moody's / S&P / Fitch ratings | Not rated (no public credit ratings) |
Facilities | A$119.7m total; A$41.4m undrawn headroom; market-rate facility to March 2028 |
Borrowings | A$73.7m (A$28.7m current, A$45.0m non-current) |
Lease liabilities | A$25.1m (A$8.2m current) |
Covenants | All complied with in FY26 |
Analyst Conclusions
Management guidance
The Board expects improved EBITDA and operating cash flow in FY27 across Personal Injury, Class Actions and the emerging IMT practice (Chairman's Letter, 28 Aug 2026). PI momentum in fee earner productivity, write-offs, fees billed and resolution quantum is expected to carry into FY27; Class Actions will focus on filing more matters and finalising litigation funding; the IMT hub will continue sourcing matters globally (FY26 Presentation). No numerical guidance is provided.
Consensus expectations
Formal consensus is not publicly verifiable. Simply Wall St's community narrative models ~5% p.a. revenue growth, a 7% profit margin and an A$0.99 fair value — treat as indicative only.
Bull case
-
PI earnings power is under-appreciated. PI alone generated A$36.6m EBITDA (+18.4%) in FY26; at a conservative 5x EV/EBITDA on PI alone (A$183m) the market is ascribing little to the Class Action book and nothing to IMT.
-
Asset backing and yield. The stock trades at ~0.5x NTA (A$1.30) with a 6.2% fully franked yield; A$366.6m of WIP is a contractual pipeline that converts into fees as matters settle.
-
Catalyst-rich class action pipeline. CFS A$140m, KFC A$28.8m, CommInsure and AMP settlements, plus a portfolio funding deal, could lift FY27 cash flow and re-rate earnings quality; an appeal win on the legacy matter offers upside.
Bear case
-
"Adjusted" is the norm, not the exception. Four consecutive years of material write-downs (A$62m cumulative FY23–FY26) imply that statutory, not adjusted, earnings are the right base — and on that basis ROE is ~4%.
-
Cash does not cover distributions. Post-lease FCF of A$7.0m vs A$8.5m dividends, cash down to A$12.5m and net debt up to A$86.3m constrain capital returns; the unused buy-back underlines this.
-
International expansion adds risk and related-party complexity. IMT affiliates in NZ and Thailand are funded by loans to Morrison-related entities, NZ NCI losses widened to A$2.9m, and the payoff is unquantified and long-dated.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| October 2026 AGM; board renewal post-Bayes | Oct 2026 | Independence and skills mix |
| Decision on appeal of legacy interlocutory judgment | FY27 H1 | Potential reversal of part of A$13.7m |
| KFC settlement final approval and distribution | Late 2026 – early 2027 | CA cash receipt |
| CFS A$140m settlement cash receipt | FY27 | Largest pending CA fee event |
| Class action portfolio funding facility | FY27 | Timing risk reduction, balance sheet relief |
| First IMT-sourced filing using A$40m facility | FY27 | Proof of concept for international strategy |
| H1 FY27 results (expected late Feb 2027) | Feb 2027 | Cash conversion, constraint trends, PI growth |
| Buy-back renewal decision | Post-Oct 2026 | Capital allocation signal |
| Tort reform announcements in QLD, NSW, VIC, WA | Ongoing | PI fee pool risk |
| Net debt and facility headroom vs A$41.4m | Ongoing | Liquidity |
Analyst verdict
Shine Justice is a structurally sound but chronically under-earning business whose valuation now discounts most of its problems. The core Personal Injury franchise is the best it has looked in years: record fees billed, 8.8% revenue growth, an 18.4% EBITDA uplift and margin expansion achieved alongside lower staff turnover. That franchise, built over 50 years and carrying an 8.5% share of a fragmented A$2.0 billion market, is the bedrock of value and is plausibly worth the entire enterprise value on its own.
The problem is everything around it. Class Actions have generated headline-grabbing social justice outcomes but have also produced a write-down in every one of the last four years, eroding management credibility and making "adjusted" earnings an unreliable anchor. Cash conversion remains weak: operating cash flow of A$19 million on A$31.7 million of statutory EBITDA, dividends exceeding post-lease free cash flow, cash falling to A$12.5 million and net debt rising to A$86.3 million. Governance is adequate rather than strong, with founder control near 50% and related-party funding of international affiliates.
At roughly 0.5x NTA, 6x statutory EV/EBITDA and a 6% fully franked yield, the market is pricing Shine as a value trap. We think the more probable FY27 path is moderate improvement — PI growth persisting, settlement cash from CFS and KFC, and a portfolio funding facility reducing timing risk — but the burden of proof sits with management to deliver a clean year with no material write-downs and operating cash flow that comfortably covers dividends. The international mass torts strategy is an option, not a thesis, until a funded IMT matter is filed and progressed.
Stance (analyst view, not investment advice): Neutral-to-constructive on valuation, with conviction contingent on two milestones in FY27 — a write-down-free result and operating cash flow above A$25 million. Failure on either would confirm the bear case that statutory ROE of ~4% is the business's true earning power.
All figures are A$ and drawn from company filings unless otherwise labelled. Analyst calculations are identified as such.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Independence | Committees | Background |
|---|---|---|---|---|
Graham Bradley AO | Chairman, NED | Independent | Chair, Nomination & Remuneration; member, Audit & Risk | BA, LLB (Hons 1), LL.M (Harvard), FAICD. Former MD Perpetual; CEO Blake Dawson; McKinsey; ex-chair Stockland, United Malt, HSBC Australia, EnergyAustralia; ex-president Business Council of Australia. Current chair Virgin Australia International Holdings, Infrastructure NSW |
Teresa Dyson | NED | Independent | Chair, Audit & Risk; member, N&R | BA, LLB (Hons), CPA, MTax, MAppFin, FAICD. Chair Southern Cross Media Group and Humm Group; Takeovers Panel member; ex-Seven West Media, Genex Power |
David Bayes | NED | Independent | Member, Audit & Risk and N&R | FAICD (Life). Ex-director Sigma Healthcare; ex-CEO Choice Hotels Australasia, Bakers Delight; ex-McDonald's Australia VP. Director since early 2020; not seeking re-election at October 2026 AGM |
Rod Douglas | NED | Not classified as independent in KMP table | None (invitee) | MBA (Bond), FAICD; 30+ years advising founder and family businesses |
Simon Morrison | Executive Director – International Mass Torts (MD to 14 Apr 2026) | Executive; substantial shareholder | — | LLB. Joined 1988 as articled clerk; MD 15+ years; former National President, Australian Lawyers Alliance; AAJ Board of Governors; QLS Accredited Specialist (PI) |
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education |
|---|---|---|---|
Carolyn Barker AM | Group Chief Executive Officer (also "Chief Change Officer") | Shine NED 2009–2020; returned as executive 2023; Group CEO from Feb 2025; enhanced role Apr 2026 | BBus, MBA, FAIM (Life). Three-decade executive career incl. private-equity-owned businesses; ex-chair Queensland Symphony Orchestra; Member of the Order of Australia (2005) |
Marc Devine | CFO and Company Secretary | From 23 Sep 2024 | BBus (Acc), FCPA, GAICD. Ex-CFO and Co Sec, Alliance Aviation Services; Mater Health; Metro North HHS |
Lisa Flynn | Chief Legal Officer | Long-serving (start date not disclosed) | LLB (Hons 1), B Com (Hons 1); abuse law specialist; INSEAD executive education |
Jodie Willey | COO, seconded as Head of Victoria | COO since 2019; CEO at time of 2013 listing | LLB (Hons); Accredited Specialist PI |
Annette O'Hara | General Counsel and Company Secretary | Since Feb 2017 | BA, LLB (Hons 1), FGIA; ex-Corrs Chambers Westgarth; Company Secretary of the Year 2022 |
Shannan Madden | Chief Marketing Officer, Shine Lawyers | — | dentsu release (Sep 2025) |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Salary and fees | STI | Other | Super | Share-based | Other LT | Total FY26 | Total FY25 |
|---|---|---|---|---|---|---|---|---|
Simon Morrison | 549,285 | 0 | 44,790 | 30,000 | 0 | 35,262 | 659,337 | 570,615 |
Carolyn Barker AM | 447,389 | 0 | 138,341 | 30,000 | 20,660 | 8,677 | 645,067 | 236,697 |
Marc Devine | 442,628 | 0 | 11,077 | 30,000 | 20,732 | 13,649 | 518,086 | 368,952 |
Jodie Willey | 440,417 | 0 | 11,077 | 30,000 | 47,407 | -5,361 | 523,540 | 492,419 |
Lisa Flynn | 449,784 | 0 | 0 | 30,000 | 48,671 | -5,277 | 523,178 | 532,871 |
Total Executive KMP | 2,329,503 | 0 | 205,285 | 150,000 | 137,470 | 46,950 | 2,869,208 | 2,423,683 |
NED | Fees | NED rights | Super | Total FY26 | — | — | — | — |
Graham Bradley AO | 205,632 | 79,738 | 24,676 | 310,046 | — | — | — | — |
Teresa Dyson | 118,444 | 15,310 | 14,213 | 147,967 | — | — | — | — |
David Bayes | 105,284 | 30,619 | 12,634 | 148,537 | — | — | — | — |
Rod Douglas | 105,284 | 30,619 | 12,634 | 148,537 | — | — | — | — |
Board & Management Changes
| Date | Change |
|---|---|
23–27 Sep 2024 | Marc Devine replaces Ravin Raj as CFO; joint Company Secretary from Dec 2024 |
Feb 2025 | Carolyn Barker AM appointed Group CEO |
14–15 Apr 2026 | Morrison moves from MD to Executive Director – IMT; Barker becomes overall leader and CODM |
Oct 2026 (AGM) | David Bayes retiring from board |
Major Shareholders
| Holder | Shares | Stake (%) | Source / date |
|---|---|---|---|
Simon Morrison (individual and nominees) | 43,718,704 | 25.8 | 2026 AR (42,339,902 + 1,378,802) |
Stephen Roche (co-founder) | ~43.7 million | ~25.8 | Simply Wall St (date not specified) |
Morrison + Roche combined voting power (associated) | — | 50.34 | ASX substantial holder notices (via TipRanks) |
Iolite Partners Limited | 19,050,000 | 11.0–11.2 | Substantial holder notice; Simply Wall St |
Fidelity International | 17,109,888 | 10.1 | Simply Wall St (may be stale) |
NCH Pty Ltd | 3,212,938 | 1.9 | Simply Wall St |
Lev Mizikovsky | 2,361,183 | 1.4 | Simply Wall St |
Dimensional Fund Advisors | 2,014,795 | 1.2 | Simply Wall St |
Jodie Willey | 1,854,273 | 1.1 | 2026 AR |
Graham Bradley AO | 753,697 | 0.4 | 2026 AR |
Lisa Flynn | 509,893 | 0.3 | 2026 AR |
Competitive Landscape
Key Competitors
| Competitor | Ownership | Segments competed | Relative positioning |
|---|---|---|---|
Slater and Gordon (Allegro Funds) | Private equity (delisted 2021) | PI, class actions | IBISWorld names Allegro Funds the largest operator in Australian PI; national brand |
Maurice Blackburn | Private partnership | PI, class actions, employment | Leading plaintiff and class action firm; strong union alignment |
Carbone Lawyers | Private | PI (NSW focus) | High-volume PI specialist |
Turner Freeman | Private | PI, dust diseases | Dust disease leader |
Stacks Law Firm | Private | PI (NSW) | Regional NSW network |
Gordon Legal | Private | Class actions, employment, PI | Also co-counsel with Shine (KFC) |
Phi Finney McDonald | Private | Class actions (shareholder, consumer) | Specialist class action firm |
William Roberts Lawyers | Private | Class actions (shareholder, social justice) | Specialist class action firm |
Piper Alderman | Private | Class actions (funded) | Commercial firm with class action practice |
Banton Group | Private | Class actions | Specialist class action firm |
Omni Bridgeway (ASX: OBL) | Listed | Litigation funding (partner/competitor for economics) | Funder capturing part of CA economics |
Ramsden Lawyers | Private | PI | Named by CB Insights as competitor |
Competitor Detail
| Metric | Shine Justice FY2026 |
|---|---|
Revenue (AUD Mn) | 209.2 |
Revenue growth (%) | 2.3 |
Statutory EBITDA margin (%) | 15.2 |
Technology spend % revenue (%) | 5.9 |



